Overview

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
Phase:
Phase 2
Details
Lead Sponsor:
Priovant Therapeutics, Inc.